Skip to main content

Table 1 Completed and ongoing ASC-based clinical trials for cardiovascular diseases

From: Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases

Clinical trial ID Phase Pathologies Enrolled number Cell delivery route Outcome measures Status Study designs Cell quantity
NCT00442806 [83] 1 STEMI 14 Intracoronary injection Safety, MACCE, feasibility, cardiac function Completed Randomized, parallel assignment, double-blind 20–40 × 106 cells
NCT02673164 2 Heart failure 138 Direct intra-myocardial injection LVESV, safety Recruiting Randomized, parallel assignment, double-blind 100 × 106 cells
NCT01449032 [86] 2 Chronic ischemic heart disease 60 Direct intra-myocardial injection Exercise test, clinical evaluation Completed Randomized, parallel assignment, double-blind 72.0 ± 44.9 × 106 cells
NCT02387723 1 Heart failure 10 Direct intra-myocardial injection Safety, LVESV, LVEF, LVEDV (ml), LV end-systolic mass (g) Completed Single group assignment, open-label 100 × 106 cells
NCT00426868 [84] 1 Ischemic heart disease 27 Direct intra-myocardial injection Safety, MACCE, feasibility, cardiac function Completed Randomized, parallel assignment, double-blind 0.4–1.2 × 106 cells/kg
NCT03092284 2 Heart failure 81 Direct intra-myocardial injection LVESV, safety, LVEF, KCCQ, 6 min walking test, Seattle Angina Questionnaire Recruiting Randomized, parallel assignment, double-blind 100 × 106 cells
NCT02052427 [85] 2 Chronic myocardial Ischemia 3 Direct intra-myocardial injection MLHFQ, mVO2, LVESV/LVEDV, EF, perfusion defect, NYHA classification, CCS classification Completed Randomized, parallel assignment, double-blind 0.8 × 106 cells/kg
NCT01216995 2 STEMI 23 Intracoronary injection Infarct size, MACCE rates Completed Randomized, parallel assignment, double-blind Not yet open
NCT01556022 [85] 2 Chronic ischemic heart disease 28 Direct intra-myocardial injection Safety, SAEs, MACE, arrhythmia assessment, feasibility, cardiac function, LVESV/LVEDV, EF Completed Randomized, parallel assignment, double-blind 0.4 × 106 cells/kg
NCT01709279 Not applicable Ischemic heart failure 6 Intracoronary injection All-cause harmful events Enrolling by invitation Single group assignment, open-label, Not yet open
  1. STEMI ST-elevation acute myocardial infarction, LVESV left ventricle end-systolic volume, LVEDV left ventricle end-diastolic volume, MACCE major adverse cardiac and cerebral events, KCCQ Kansas City Cardiomyopathy Questionnaire, MLHFQ Minnesota Living with Heart Failure Questionnaire, NYHA New York Heart Function Assessment, CCS Canadian Cardiovascular Society, SAEs serious adverse events, MACE major adverse cardiac events